LRRK2 inhibitors (Standigm)

N/A

Report date: 2025/03/20 15:13:34
NME

Base Information

Drug NameLRRK2 inhibitors (Standigm)
Drug Alias NameLeucine rich serine threonine kinase 2 inhibitors (Standigm)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStandigm Inc
China Registration ClassN/A

Develop Information

Active CompaniesStandigm Inc
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A